ReviewFrontiers in immunology2026
Roles of exosomal non-coding RNAs in osteoarthritis.
Review in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
- Erratum issued
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Osteoarthritis (OA) is increasingly recognized as a chronic low-grade inflammatory joint disorder characterized by progressive cartilage degeneration, synovial inflammation, subchondral bone remodeling, and disrupted intercellular communication. Growing evidence indicates that exosomal non-coding RNAs (ncRNAs), including microRNAs, long non-coding RNAs, and circular RNAs, are key regulators of the OA microenvironment. By mediating intercellular signal transfer among chondrocytes, synovial fibroblasts, macrophages, osteoblasts, and osteoclasts, exosomal ncRNAs influence inflammatory mediator production, immune cell polarization, extracellular matrix metabolism, and osteochondral homeostasis. These regulatory effects are closely associated with major signaling pathways, including NF-κB, PI3K/AKT/mTOR, MAPK, and inflammasome-related cascades. Beyond their mechanistic roles in disease progression, exosomal ncRNAs also show strong potential as minimally invasive biomarkers for OA diagnosis and staging, as well as therapeutic agents or delivery vehicles for targeted intervention. This review focuses on the mechanisms of exosomal ncRNAs in modulating the osteoarthritis inflammation microenvironment, highlighting the potential of exosomal ncRNAs in osteoarthritis diagnosis and the prospects for their use in osteoarthritis medicine.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.